Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3322207 in Healthy and Hypertensive Subjects
NCT03590860Phase 1Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3322207 in hypertension (HTN) (5 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with One or More Serious Adverse Events (Part A), Number of Participants with One or More Serious Adverse Events (Part B) and 1 more. Started Jul 2018; status: terminated.
02
Drugs
LY3322207
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT03590860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03590860.